Monthly injections for NF1 skin bumps
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This study tests if a monthly injection of deoxycholate can shrink or reduce the number of visible skin bumps (cutaneous neurofibromas) in people with NF1. It is designed for adults with at least 6 bumps that can be treated and monitored.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have NF1 confirmed by genetic testing or a specific checklist of signs.
- You are 18 years or older.
- You have 6 or more visible skin bumps (at least 2 mm each) on your trunk, arms, or legs that you want treated.
- You have no known allergy to deoxycholate (the study drug).
- You are not currently tanning the area where the injections would be given.
- You are not pregnant (if female).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether the medicine abemaciclib can shrink or slow the growth of “atypical neurofibromas” in people with NF1. Participants take pills and undergo regular check-ups, including MRI scans to measure the tumor.
This Phase 2 trial tests HL-085 in adults with neurofibromatosis type 1 (NF1) who have a nerve tumor (plexiform neurofibroma) that cannot be removed by surgery and causes symptoms. It aims to shrink or control the tumor by measuring changes on MRI and monitoring side effects.
This trial tests a daily capsule called semetinib for adults with type 1 neurofibromatosis (NF1) who have at least one measurable tumor. It aims to shrink or slow tumor growth, especially for tumors that can be surgically removed.
This trial tests an investigational drug called smethinib (a type of targeted therapy) for people with neurofibromatosis type 1 whose tumors have grown into the brain, spine, or other important organs and cannot be removed by surgery. The goal is to see if the drug can shrink or slow the growth of these tumors.
This trial tests a combination of two targeted drugs (cabozantinib and selumetinib) for people with NF1 who have plexiform neurofibromas that are growing or causing significant problems. The goal is to see if this combination can shrink or slow the growth of these tumors.
This study tracks people with NF1 to watch for when benign nerve tumors turn cancerous. It uses regular MRI scans to catch changes early, which could help guide treatment decisions.
Hear when a new Neurofibromatosis 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.